Zeng, Xuemei
Chen, Yijun
Sehrawat, Anuradha
Lee, Jihui
Lafferty, Tara K.
Kofler, Julia
Berman, Sarah B.
Sweet, Robert A.
Tudorascu, Dana L.
Klunk, William E.
Ikonomovic, Milos D.
Pfister, Anna
Zetterberg, Henrik
Snitz, Beth E.
Cohen, Anne D.
Villemagne, Victor L.
Pascoal, Tharick A.
Kamboh, M. llyas
Lopez, Oscar I.
Blennow, Kaj
Karikari, Thomas K. http://orcid.org/0000-0003-1422-4358
Funding for this research was provided by:
National Institutes of Health (R01 AG083874)
Article History
Received: 25 July 2023
Accepted: 13 February 2024
First Online: 15 May 2024
Declarations
:
: Not applicable.
: Not applicable.
: MDI has received research funding from GE Healthcare and Avid Radiopharmaceuticals. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant and at advisory boards for Acumen, ALZPath, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. The other authors declare no competing interests.